Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: A systematic review of prospective studies

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Franchini, M ^a   Makris, M ^b   Santagostino, E ^c   Coppola, A ^d   Mannucci, Pier Mannuccio ^c  

^a CARLO POMA HOSPITAL   (Italy)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adverse reaction; Factor IX; Factor VIII; Safety; Serious reactions; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; RECOMBINANT VON WILLEBRAND FACTOR;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BLEEDING; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FEVER; HEART ATRIUM FIBRILLATION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; IRRITABILITY; LEG PAIN; NAUSEA; PERIPHERAL EDEMA; PHLEBITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SNEEZING; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; URTICARIA; VOMITING; VON WILLEBRAND DISEASE;

COAGULANTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASES;

EID: 84860316421     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02745.x     Document Type: Review

References (74)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Key NS, Negrier C. Coagulation factor concentrates: past, present and future. Lancet 2007; 370: 439-48.
3. Mannucci PM, Franchini M, Castaman G, Federici AB; on behalf of AICE (Italian Association of Haemophilia Centres). Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
4. Koster T, Blann AD, Brief E et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
5. Makris M, Colvin B, Gupta V et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
6. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
7. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-62.
8. European Commission. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at Accessed October 10, 2011.
9. Schwartz RS, Abildgaard CF, Aledort LM et al. ; and the Recombinant Factor VIII Study Group. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl I Med 1990; 323: 1800-5.
10. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
11. Bray GL, Gomperts ED, Courter SG. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients. Blood 1994; 83: 2428-35.
12. Aygoren-Pursun E, Sharrer I; The German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
13. White GC II, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
14. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
15. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
16. Scharrer I, Brackmann HH, Sultan I et al. Efficacy of sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe hemophilia A. Haemophilia 2000; 6: 614-8.
17. Powell JS, Bush M, Harrison J et al. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000; 6: 140-9.
18. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38(Suppl. 4): 44-51.
19. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38(Suppl. 4): 52-9.
20. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A; Kogenate FS Study Group. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
21. Rothschild C, Scharrer I, Brackmann HH et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8(Suppl. 2): 10-4.
22. Lusher JM, Lee CA, Kessler CM, Bedrosian CL; ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
23. Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol 2003; 78: 467-74.
24. Vossebeld PJM, Tissing MH, van den Berg HM et al. In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A. Haemophilia 2003; 9: 157-63.
25. Tarantino MD, Collins PW, Hay CR et al. ; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
26. Lusher J, Abildgaard C, Arkin S et al. Recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
27. Wolf DM, Rokicka-Milewska R, Lopaciuk S et al. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Haemophilia 2004; 10: 438-48.
28. Smith MP, Giangrande P, Pollman H et al. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444-51.
29. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 3: 457-67.
30. Pollmann H, Externest D, Ganser A et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13: 131-43.
31. Di Paola J, Smith MP, Klamroth R et al. Refacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
32. Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia 2007; 13: 351-6.
33. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
34. Nemes L, Lissitchkov T, Klukowska A et al. Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe hemophilia A. Haemophilia 2007; 13: 9-11.
35. Blanchette VS, Shapiro AD, Liesner RJ et al. ; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
36. Delumeau JC, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost 2008; 100: 32-7.
37. Musso R, Santagostino E, Faradji A et al. ; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
38. Negrier C, Shapiro A, Berntorp E et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of ADVATE in previously treated patients. Thromb Haemost 2008; 100: 217-23.
39. Shapiro A, Gruppo R, Pabinger I et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther 2009; 9: 273-83.
40. Petrini P, Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study. Haemophilia 2009; 100: 32-7.
41. Young JH, Liu HC, Hsueh EJ et al. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A. Haemophilia 2009; 15: 968-70.
42. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
43. Oldenburg J, Goudemand J, Valentino L et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16: 866-77.
44. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
45. Vidovic N, Musso R, Klamroth R, Enriquez MM, Achilles K. Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. Haemophilia 2010; 16: 66-71.
46. Wyndiga J, Rusen L, Gruppo R et al. BBDrFVIII (Morotocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study. Haemophilia 2010; 16: 731-9.
47. Dmoszynska A, Kuliczkowski K, Hellmann A et al. Clinical assessment of Optivate, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. Haemophilia 2011; 17: 456-62.
48. Matysiak M, Bobrowska H, Balwierz W et al. Clinical experience with Optivate, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. Haemophilia 2011; 17: 737-42.
49. ®: interim report from an ongoing prospective clinical study. Haemophilia 2011; 17: 399-406.
50. Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127: 247-53.
51. Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for no-demand treatment of Chinese patients with haemophilia A. Haemophilia 2011; 17: 191-5.
52. Hay CRM, Hellmann A, Dmoszynska A et al. Experience with Optivate, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery. Haemophilia 2011; 17: 428-32.
53. Shapiro AD, Ragni MV, Lusher JM et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
54. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
55. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL; Recombinant FIX Surgical Study Group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
56. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
57. Hoots WK, Leissinger C, Stabler S et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. Haemophilia 2003; 9: 164-72.
58. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
59. Ruiz-Saez A, Hing A, Arguello A et al. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. Haemophilia 2005; 11: 583-8.
60. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe hemophilia B. Haemophilia 2007; 13: 233-43.
61. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6years of age with severe hemophilia B. Haemophilia 2010; 16: 460-8.
62. Serban M, Skotnicki AB, Colovic M et al. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe hemophilia B. Haemophilia 2011; Aug 3. doi: 10.1111/j.1365-2516.2011.02624.x. (Epub ahead of print).
63. Lissitchov T, Matysiak M, Zavilska K et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
64. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Wilebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
65. Auerswald G, Eberspacher B, Engl W et al. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate). Semin Thromb Hemost 2002; 28: 203-13.
66. Thompson AR, Gill GC, Ewenstein BM, Mueller-Veltens G, Schwartz BA; for the Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
67. Ver Elst KMM, van Vliet HDM, Kappers-Klunne MC, Leebeek FWG. In vitro studies, pharmacokinetic studies and clincal use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004; 92: 67-74.
68. Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective International study results. Haemophilia 2007; 13(Suppl. 5): 25-32.
69. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; for the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (HAEMATE P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
70. Borel-Derlon A, Federici AB, Roussel-Robert V et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
71. Berntorp E, Windyga J; The European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-30.
72. Dunkley S, Baker RI, Pidcock M et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. Haemophilia 2010; 16: 615-24.
73. Windyga J, von Depka.Prondzinski M; on behalf of the European Wilate Study Group. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-9.
74. Makris M, Fischer K; European Haemophilia Safety Surveillance System (EUHASS). Annual Report. 217 March 2011. ISBN 978-1-908155-03-0.